Optimally Choosing Medication Type for Patients With Opioid Use Disorder

Area of Science:

• Addiction Medicine
• Pharmacotherapy
• Clinical Trials

Background:

• Opioid Use Disorder (OUD) treatment often involves a choice between methadone, buprenorphine-naloxone, and extended-release naltrexone.
• Current treatment assignment is typically based on the healthcare setting rather than individual patient characteristics.
• Optimizing medication matching could potentially reduce the risk of return to regular opioid use (RROU).

Purpose of the Study:

• To develop an individualized rule for assigning OUD medications to minimize RROU.
• To estimate the potential reduction in RROU risk if this rule were implemented.

Main Methods:

• Analysis of data from 1,459 patients across three comparative effectiveness trials (CTN0027, CTN0030, CTN0051).
• Patients were treated with either injection extended-release naltrexone (XR-NTX), sublingual buprenorphine-naloxone (BUP-NX), or oral methadone.
• An individualized treatment assignment rule was derived to minimize 12-week RROU risk.

Main Results:

• Applying the derived rule showed a reduced RROU risk compared to universal methadone treatment (RR=0.79) or universal XR-NTX treatment (RR=0.71).
• The rule-based assignment resulted in a similar RROU risk compared to universal BUP-NX treatment (RR=0.92).

Conclusions:

• An individualized medication assignment strategy for OUD can potentially lower the risk of relapse.
• Personalized matching may offer advantages over current treatment paradigms, particularly compared to universal methadone or XR-NTX approaches.